Virax Biolabs Group Stock (NASDAQ:VRAX)


OwnershipChart

Previous Close

$2.89

52W Range

$2.50 - $25.00

50D Avg

$4.38

200D Avg

$7.06

Market Cap

$546.81K

Avg Vol (3M)

$2.22M

Beta

1.33

Div Yield

-

VRAX Company Profile


Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

GB

Employees

26

IPO Date

Jul 21, 2022

Website

VRAX Performance


Peer Comparison


TickerCompany
NCELNewcelX Ltd.
WINTWindtree Therapeutics, Inc.
ARTLArtelo Biosciences, Inc.
XRTXXORTX Therapeutics Inc.
GTBPGT Biopharma, Inc.
DRMADermata Therapeutics, Inc.
MLECMoolec Science S.A.
ELABPMGC Holdings Inc.